HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares rose 7.5% on Tuesday . The company traded as high as $16.44 and last traded at $16.17. Approximately 64,171 shares were traded during trading, a decline of 40% from the average daily volume of 106,190 shares. The stock had previously closed at $15.04.
Analysts Set New Price Targets
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.
Get Our Latest Stock Analysis on HUTCHMED
HUTCHMED Price Performance
The firm has a 50 day simple moving average of $14.88 and a 200-day simple moving average of $16.39. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.
Institutional Trading of HUTCHMED
Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC raised its stake in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after acquiring an additional 49,366 shares during the last quarter. XY Capital Ltd acquired a new stake in HUTCHMED during the 4th quarter worth approximately $673,000. ABC Arbitrage SA bought a new stake in HUTCHMED in the 4th quarter valued at $500,000. Renaissance Technologies LLC lifted its holdings in shares of HUTCHMED by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after purchasing an additional 29,239 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of HUTCHMED during the 4th quarter worth approximately $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
